Sitagliptin and other gliptins - Why prescribe them?

S.A. Doggrell, Simon B. Dimmitt

    Research output: Contribution to journalEditorial

    5 Citations (Scopus)


    © 2016 Informa UK Limited, trading as Taylor & Francis Group. Introduction: In 2008, the Federal Drug Administration (FDA) required all new glucose-lowering therapies to show cardiovascular safety, and this applies to the dipeptidyl peptidase (DPP)-4 inhibitors (gliptins). At present, there is contradictory evidence on whether the gliptins increase hospitalizations for heart failure. Areas covered: This is an evaluation of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in high risk cardiovascular subjects with type 2 diabetes [1]. TECOS demonstrated non-inferiority for sitagliptin over placebo for the primary outcome, which was cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. There was no difference in the rate of hospitalization for heart failure between sitagliptin and placebo. Expert Opinion: Despite the results of TECOS, debate over the effects of sitagliptin on the rates of hospitalizations for heart failure continues with some recent studies suggesting increased rates. Recently, empagliflozin (an inhibitor of sodium-glucose cotransporter 2) has been shown to reduce cardiovascular outcomes in subjects with type 2 diabetes, including the rates of hospitalization for heart failure. In our opinion, these positive findings with empagliflozin suggest that it should be prescribed in preference to the gliptins, including sitagliptin, unless any positive cardiovascular outcomes are reported for the gliptins.
    Original languageEnglish
    Pages (from-to)757-760
    Number of pages4
    JournalExpert Opinion on Pharmacotherapy
    Issue number6
    Publication statusPublished - 12 Apr 2016


    Dive into the research topics of 'Sitagliptin and other gliptins - Why prescribe them?'. Together they form a unique fingerprint.

    Cite this